학술논문
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development
Document Type
Article
Author
Source
In Contemporary Clinical Trials 2011 32(3):324-332
Subject
Language
ISSN
1551-7144